JOHANNESBURG (Reuters) - Aspen Pharmacare plans to start supplying Johnson & Johnson COVID-19 vaccine doses from its facility in South Africa before the end of June, its chief executive said on Friday.
Stephen Saad told Reuters in an interview that the technology transfer from J&J has “gone very well and we are now committing commercial supply in our financial year.”
The company’s financial year ends in June.
The company has committed 300 million COVID-19 vaccine doses, however the final amount that will be manufactured will depend on demand from J&J, he said.
Reporting by Promit Mukherjee; editing by Jason Neely
Our Standards: The Thomson Reuters Trust Principles.